Compare KFY & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFY | BEAM |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | 1998 | 2019 |
| Metric | KFY | BEAM |
|---|---|---|
| Price | $68.04 | $28.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $73.00 | $50.75 |
| AVG Volume (30 Days) | 331.8K | ★ 2.0M |
| Earning Date | 06-17-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | 42.41 | ★ 82.31 |
| EPS | ★ 3.84 | N/A |
| Revenue | ★ $1,819,519,000.00 | $24,000.00 |
| Revenue This Year | $6.92 | N/A |
| Revenue Next Year | $3.25 | $33.77 |
| P/E Ratio | $17.35 | ★ N/A |
| Revenue Growth | 12.20 | ★ 33.33 |
| 52 Week Low | $58.27 | $15.60 |
| 52 Week High | $78.50 | $36.44 |
| Indicator | KFY | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 60.83 | 48.66 |
| Support Level | $65.79 | $28.50 |
| Resistance Level | $68.54 | $29.06 |
| Average True Range (ATR) | 1.83 | 1.97 |
| MACD | 0.04 | -0.48 |
| Stochastic Oscillator | 93.51 | 32.57 |
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.